095700.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:30):

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea...

Stats
Dzisiejszy wolumen	62 989.00
Średni wolumen	217 175
Kapitalizacja rynkowa	318.33B
EPS	KRW0 ( 2024-02-08 )
Następna data zysków	( KRW229.00 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW12.30 (0.16%)

Wolumen Korelacja

Długi: -0.10 (neutral)

Krótki: 0.37 (neutral)

Signal:(55.461) Neutral

Genexine, Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genexine, Inc. Korelacja - Waluta/Towar

0.45
( neutral )

0.17
( neutral )

-0.06
( neutral )

0.48
( neutral )

-0.11
( neutral )

Genexine, Inc. Finanse

Annual	2023
Przychody:	KRW4.43B
Zysk brutto:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2023
Przychody:	KRW4.43B
Zysk brutto:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2022
Przychody:	KRW16.14B
Zysk brutto:	KRW7.30B (45.26 %)
EPS:	KRW-1 326.23

Financial Reports:

No articles found.

Genexine, Inc.

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.